CD83

CD83

a type I transmembrane protein, present on dendritic cells, Langerhans cells, B cells, and interdigitating reticular cells; may play a role in antigen presentation or the cellular interactions that follow lymphocyte activation.
References in periodicals archive ?
DC-SIGN-positive cells appear to be immature dendritic cells in that they did not express the dendritic cell maturation molecule CD83.
Among the up-regulated gene expression, IL-1[alpha], TNF-[alpha], CD69 and CD83 were related to anti-tumour activities.
Expression of CCR6 and CD83 by cytokine-activated human neutrophils.
Transcription analysis of 44 CD genes was also carried out, indicating 24 CD genes (CD3E, CD244, CD69, CD247, CD40L, CD38, CD5L, CD44, CD5, CD83, CD163L1, CD36, CD14, CD28, CD200R1A, CD40, CD59, CD200, CD4, CD2, CD72, CD180, CD79B, and CD93) to be markedly increased by 2.
Group 1: In the therapeutic sub-group of ten patients, there was one sample before treatment in which both CD1a and CD83 were negative.
Table I: Product pipeline, Description Indication Status AGS 003 (1) Metastatic Renal Cell P II Carcinoma CD83 Transplantation rejection/ Pre-clinical AGS-005 (1) Chronic L c Lymphocytic PI/II Leukaemia autoimmune disorders Monoclonal antibody (2) Lupus Pre-clinical AGS-004 (1) HIV PI (1).
Combining our knowledge of dendritic cells and expertise in immunology to develop an immunotherapy platform based on CD83 may lead to an effective therapy for solid organ transplantation," said Jeff Abbey, president and chief executive officer of Argos.
Abbey will discuss the Company's Arcelis[TM] personalized immunotherapy programs in metastatic renal cell carcinoma (RCC) and HIV, both in Phase 2 clinical trials; its anti-IFN-alpha monoclonal antibody, which is in a Phase 1 trial in systemic lupus erythematosus (SLE) patients; and its CD83 recombinant protein, an immunomodulator for inflammatory and autoimmune diseases and transplantation rejection.
Soluble CD83 (sCD83) is a glycoprotein expressed on the cell surface of mature dendritic cells (DCs), the most potent stimulators of immune responses.
Argos Therapeutics today announced the presentation of new information on its soluble CD83 (sCD83) protein program in a poster session at the 2009 American Transplant Congress, held May 30-June 3 in Boston.
Governmental Affairs and Clinical Development of Immunotech Laboratories, and founder of ACT UP HIV/AIDS activist group, "Laboratory analysis indicates that IPF is able to mediate maturation of dendrite cells in vitro, as determined by up-regulation of MHC class-ll, CD86 and CD83 molecules, regulate pro-inflammatory cytokines IL-12 and INFy, and enhanced T-cells' stimulatory capacity.